SCHEMBL890155

SCHEMBL890155

CC(=O)Cc1nnn[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30428049 0.98 CA12 (0.30)
SCHEMBL1259219 0.78
SCHEMBL7353703 0.78 KDM6B (0.33)
SCHEMBL10369757 0.77 CA12 (0.33)
Acetic Acid SCHEMBL4111573 0.77 HCAR2 (0.32)
SCHEMBL10856590 0.77 F2 (0.32)
SCHEMBL12676638 0.75 GAA (0.41)
SCHEMBL12669764 0.74 POLB (0.39)
SCHEMBL9465527 0.74 KDM4E (0.38)
SCHEMBL12118230 0.74 PAOX (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209028-A1 CNP COMPOUNDS NOVO NORDISK A/S (DK) 2024-06-27 US disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-20230295135-A1 CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF ALGEN BIOTECHNOLOGIES, INC. 2023-09-21 US disclosed
US-20230295135-A1 CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF ALGEN BIOTECHNOLOGIES, INC. 2023-09-21 US disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-11591322-B2 Certain chemical compositions and methods of use thereof ALGEN BIOTECHNOLOGIES, INC. (US) 2023-02-28 US disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed
WO-2021231892-A1 CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF ALGEN BIOTECHNOLOGIES, INC. (US) 2021-11-18 WO disclosed
EP-3490983-B1 DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-02-17 EP disclosed
WO-2018026620-A1 DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-08 WO disclosed
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2009-10-08 US disclosed
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-12 US disclosed
US-20090005387-A1 QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2009-01-01 US disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed
US-20080076700-A1 Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone NOVO NORDISK A/S (DK) 2008-03-27 US disclosed
US-20080050336-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-28 US disclosed
US-20080032936-A1 Quinoxalinyl tripeptide hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2008-02-07 US disclosed
US-20080008681-A1 MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-01-10 US disclosed
US-20070299078-A1 Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors ENANTA PHARMACEUTICALS, INC. 2007-12-27 US disclosed